NCT04922827View on ClinicalTrials.gov

Infliximab in the Treatment of Patients With Severe COVID-19 Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

July 1, 2023

Conditions
COVID-19
Interventions
DRUG

Infliximab

single intravenous administration of 5 milligrams/kilogram

OTHER

Standard of Care

Standard of Care

Trial Locations (4)

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

36043

Klinikum Fulda, Fulda

44892

Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum

07747

Jena University Hospital, Jena

Sponsors

Collaborators (1)

Celltrion
All Listed Sponsors
collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

Celltrion

INDUSTRY

lead

Jena University Hospital

OTHER

NCT04922827 - Infliximab in the Treatment of Patients With Severe COVID-19 Disease | Biotech Hunter | Biotech Hunter